Reuters logo
BRIEF-Seres Therapeutics completes enrollment in early stage study of ulcerative colitis drug
June 5, 2017 / 11:36 AM / 6 months ago

BRIEF-Seres Therapeutics completes enrollment in early stage study of ulcerative colitis drug

June 5 (Reuters) - Seres Therapeutics Inc-

* Seres Therapeutics announces completion of enrollment for ser-287 phase 1b study in patients with ulcerative colitis

* Seres Therapeutics Inc - study results expected in second half of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below